{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:08:09Z","timestamp":1777522089374,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["APP1152390"],"award-info":[{"award-number":["APP1152390"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["17\/414"],"award-info":[{"award-number":["17\/414"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1092957"],"award-info":[{"award-number":["APP1092957"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001232","name":"Royal Australasian College of Physicians","doi-asserted-by":"publisher","award":["Jacquot Research Establishment Award 2017"],"award-info":[{"award-number":["Jacquot Research Establishment Award 2017"]}],"id":[{"id":"10.13039\/501100001232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007658","name":"Baxter Healthcare Corporation","doi-asserted-by":"publisher","award":["Baxter Medication Delivery Grant 2017"],"award-info":[{"award-number":["Baxter Medication Delivery Grant 2017"]}],"id":[{"id":"10.13039\/100007658","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Delayed graft function, or the requirement for dialysis due to poor kidney function, is a frequent complication of deceased donor kidney transplantation that is associated with inferior outcomes. Intravenous fluids with a high chloride content, such as isotonic sodium chloride (0.9% saline), are widely used in transplantation but may increase the risk of poor kidney function. The primary objective of the BEST-Fluids trial is to compare the effect of a balanced low-chloride crystalloid, Plasma-Lyte 148 (Plasmalyte), versus 0.9% saline on the incidence of DGF in deceased donor kidney transplant recipients. This article describes the statistical analysis plan for the trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and design<\/jats:title>\n                <jats:p>BEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-centre, double-blind, randomised controlled trial. Eight hundred patients (adults and children) in Australia and New Zealand with end-stage kidney disease admitted for a deceased donor kidney transplant were randomised to intravenous fluid therapy with Plasmalyte or 0.9% saline in a 1:1 ratio using minimization. The primary outcome is delayed graft function (dialysis within seven days post-transplant), which will be modelled using a log-binomial generalised linear mixed model with fixed effects for treatment group, minimization variables, and ischaemic time and a random intercept for study centre. Secondary outcomes including early kidney transplant function (a ranked composite of dialysis duration and the rate of graft function recovery), treatment for hyperkalaemia, and graft survival and will be analysed using a similar modelling approach appropriate for the type of outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>BEST-Fluids will determine whether Plasmalyte reduces the incidence of DGF and has a beneficial effect on early kidney transplant outcomes relative to 0.9% saline and will inform clinical guidelines on intravenous fluids for deceased donor kidney transplantation. The statistical analysis plan describes the analyses to be undertaken and specified before completion of follow-up and locking the trial databases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Australian New Zealand Clinical Trials Registry <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=372450\">ACTRN12617000358347<\/jats:ext-link>. Prospectively registered on 8 March 2017<\/jats:p>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> identifier <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03829488\">NCT03829488<\/jats:ext-link>. Registered on 4 February 2019<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05989-w","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T10:03:43Z","timestamp":1642500223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Statistical analysis plan for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a randomised controlled trial of the effect of intravenous fluid therapy with balanced crystalloid versus saline on the incidence of delayed graft function in deceased donor kidney transplantation"],"prefix":"10.1186","volume":"23","author":[{"given":"Elaine M.","family":"Pascoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Chadban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magid A.","family":"Fahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmel M.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-9087","authenticated-orcid":false,"given":"Michael G.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the BEST-fluids Investigators and the Australasian Kidney Trials Network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"issue":"10","key":"5989_CR1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/TP.0b013e3182a19348","volume":"96","author":"DH Mallon","year":"2013","unstructured":"Mallon DH, Summers DM, Bradley JA, Pettigrew GJ. Defining delayed graft function after renal transplantation: simplest is best. Transplantation. 2013;96(10):885\u20139. https:\/\/doi.org\/10.1097\/TP.0b013e3182a19348.","journal-title":"Transplantation"},{"issue":"8","key":"5989_CR2","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1097\/TP.0b013e3182855544","volume":"95","author":"NM Butala","year":"2013","unstructured":"Butala NM, Reese PP, Doshi MD, Parikh CR. Is delayed graft function causally associated with long-term outcomes after kidney transplantation? Instrumental variable analysis. Transplantation. 2013;95(8):1008\u201314. https:\/\/doi.org\/10.1097\/TP.0b013e3182855544.","journal-title":"Transplantation"},{"issue":"10","key":"5989_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1097\/01.TP.0000121763.44137.FA","volume":"77","author":"EG Hagenmeyer","year":"2004","unstructured":"Hagenmeyer EG, Haussler B, Hempel E, Grannas G, Kalo Z, Kilburg A, et al. Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications. Transplantation. 2004;77(10):1545\u201350. https:\/\/doi.org\/10.1097\/01.TP.0000121763.44137.FA.","journal-title":"Transplantation"},{"issue":"4","key":"5989_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/ki.2015.190","volume":"88","author":"WK Wu","year":"2015","unstructured":"Wu WK, Famure O, Li Y, Kim SJ. Delayed graft function and the risk of acute rejection in the modern era of kidney transplantation. Kidney Int. 2015;88(4):851\u20138. https:\/\/doi.org\/10.1038\/ki.2015.190.","journal-title":"Kidney Int"},{"issue":"3","key":"5989_CR5","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/ndt\/gfn667","volume":"24","author":"SG Yarlagadda","year":"2009","unstructured":"Yarlagadda SG, Coca SG, Formica RNJ, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009;24(3):1039\u201347. https:\/\/doi.org\/10.1093\/ndt\/gfn667.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"5989_CR6","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1016\/S0041-1345(02)03593-5","volume":"34","author":"CM O'Malley","year":"2002","unstructured":"O'Malley CM, Frumento RJ, Bennett-Guerrero E. Intravenous fluid therapy in renal transplant recipients: results of a US survey. Transplant Proc. 2002;34(8):3142\u20135. https:\/\/doi.org\/10.1016\/S0041-1345(02)03593-5.","journal-title":"Transplant Proc"},{"issue":"4","key":"5989_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.5492\/wjccm.v5.i4.235","volume":"5","author":"L Weinberg","year":"2016","unstructured":"Weinberg L, Collins N, Van Mourik K, Tan C, Bellomo R. Plasma-Lyte 148: A clinical review. World J Crit Care Med. 2016;5(4):235\u201350. https:\/\/doi.org\/10.5492\/wjccm.v5.i4.235.","journal-title":"World J Crit Care Med"},{"issue":"6","key":"5989_CR8","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/ki.2014.105","volume":"86","author":"DN Lobo","year":"2014","unstructured":"Lobo DN, Awad S. Should chloride-rich crystalloids remain the mainstay of fluid resuscitation to prevent 'pre-renal' acute kidney injury? Kidney Int. 2014;86(6):1096\u2013105. https:\/\/doi.org\/10.1038\/ki.2014.105.","journal-title":"Kidney Int"},{"issue":"3","key":"5989_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1172\/JCI110820","volume":"71","author":"CS Wilcox","year":"1983","unstructured":"Wilcox CS. Regulation of renal blood flow by plasma chloride. J Clin Investig. 1983;71(3):726\u201335. https:\/\/doi.org\/10.1172\/JCI110820.","journal-title":"J Clin Investig"},{"issue":"1","key":"5989_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/bjs.9651","volume":"102","author":"ML Krajewski","year":"2015","unstructured":"Krajewski ML, Raghunathan K, Paluszkiewicz SM, Schermer CR, Shaw AD. Meta-analysis of high- versus low-chloride content in perioperative and critical care fluid resuscitation. Br J Surg. 2015;102(1):24\u201336. https:\/\/doi.org\/10.1002\/bjs.9651.","journal-title":"Br J Surg"},{"issue":"9","key":"5989_CR11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1711586","volume":"378","author":"WH Self","year":"2018","unstructured":"Self WH, Semler MW, Wanderer JP, Wang L, Byrne DW, Collins SP, et al. Balanced crystalloids versus saline in noncritically ill adults. New Engl J Med. 2018;378(9):819\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1711586.","journal-title":"New Engl J Med"},{"issue":"9","key":"5989_CR12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1711584","volume":"378","author":"MW Semler","year":"2018","unstructured":"Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW, et al. Balanced crystalloids versus saline in critically ill adults. New Engl J Med. 2018;378(9):829\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1711584.","journal-title":"New Engl J Med"},{"issue":"1","key":"5989_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/SLA.0b013e318256be72","volume":"256","author":"AH Chowdhury","year":"2012","unstructured":"Chowdhury AH, Cox EF, Francis ST, Lobo DN. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte(R) 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg. 2012;256(1):18\u201324. https:\/\/doi.org\/10.1097\/SLA.0b013e318256be72.","journal-title":"Ann Surg"},{"issue":"4","key":"5989_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/bja\/aex163","volume":"119","author":"L Weinberg","year":"2017","unstructured":"Weinberg L, Harris L, Bellomo R, Ierino F, Story D, Eastwood G, et al. Effects of intraoperative and early postoperative normal saline or Plasma-Lyte 148\u00ae on hyperkalaemia in deceased donor renal transplantation: a double-blind randomized trial. Br J Anaesth. 2017;119(4):606\u201315. https:\/\/doi.org\/10.1093\/bja\/aex163.","journal-title":"Br J Anaesth"},{"key":"5989_CR15","doi-asserted-by":"crossref","unstructured":"Wan S, Roberts MA, Mount P. Normal saline versus lower-chloride solutions for kidney transplantation. Cochrane Database Syst Rev. 2016; Issue 8. Art. No.: CD010741:Art. No.: CD010741.","DOI":"10.1002\/14651858.CD010741.pub2"},{"issue":"1","key":"5989_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13063-020-04359-2","volume":"21","author":"MG Collins","year":"2020","unstructured":"Collins MG, Fahim MA, Pascoe EM, Dansie KB, Hawley CM, Clayton PA, et al. Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantation. Trials. 2020;21(1):428.","journal-title":"Trials"},{"issue":"23","key":"5989_CR17","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/jama.2017.18556","volume":"318","author":"C Gamble","year":"2017","unstructured":"Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dor\u00e9 C, et al. Guidelines for the content of statistical analysis plans in clinical trials. JAMA. 2017;318(23):2337\u201343. https:\/\/doi.org\/10.1001\/jama.2017.18556.","journal-title":"JAMA"},{"issue":"1","key":"5989_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s13063-017-2248-1","volume":"18","author":"C Pedroza","year":"2017","unstructured":"Pedroza C, Truong VTT. Estimating relative risks in multicenter studies with a small number of centers \u2014 which methods to use? A simulation study. Trials. 2017;18(1):512. https:\/\/doi.org\/10.1186\/s13063-017-2248-1.","journal-title":"Trials"}],"updated-by":[{"DOI":"10.1186\/s13063-022-06050-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05989-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05989-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05989-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T07:07:09Z","timestamp":1644304029000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05989-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5989"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05989-w","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13063-022-06050-0","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"24 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13063-022-06050-0","URL":"https:\/\/doi.org\/10.1186\/s13063-022-06050-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the BEST-Fluids trial was obtained from the Northern A Health and Disability Ethics Committee (approval number 17\/NTA\/62), for New Zealand, and from the Sydney Local Health District Human Research Ethics Committee, Royal Prince Alfred Hospital (approval numbers X17\u20130201 and HREC\/17\/RPAH\/308), for Australia. The study has received local governance approvals at each of the participating sites. Protocol amendments are submitted to and approved by the ethics committees prior to implementation. Written informed consent has been obtained from all participants in the study. For children, consent has been obtained from parents or guardians, with assent sought from adolescents and children where appropriate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication is not applicable since there are no identifying images or other personal or clinical details of participants presented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MC has received research support from Baxter Healthcare Pty Ltd., the manufacturer of Plasmalyte, through a Baxter Investigator Initiated Research grant that provided fluids for this trial (commercial value of US $36,270). EP is an employee of the Sponsor, The University of Queensland. DJ has received consultancy fees, research grants, speaker\u2019s honoraria, and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from Astra Zeneca and AWAK, speaker\u2019s honoraria and travel sponsorships from ONO, and BI & Lilly, and travel sponsorships from ONO and Amgen. CH has received research grants from Baxter and NHMRC related to the current project. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}